section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash

EENT: nasopharyngitis, sinus congestion

GI: abdominal pain, diarrhea, dry mouth

GU: urinary tract infection

MS: muscle twitching, myalgia

Neuro: dizziness, sedation, anxiety, confusion, fatigue, gait disturbances, memory impairment, SUICIDAL THOUGHTS/BEHAVIORS, tremor

Misc: physical dependence

Interactions

Drug-drug:

Availability

Route/Dosage

Renal Impairment

Hepatic Impairment

US Brand Names

Zurzuvae

Action

  • Although not fully understood, thought to be related to positive allosteric modulation of GABA-A receptors.
Therapeutic effects:
  • Reduction in depressive symptoms

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: corticosteroids, gamma aminobutyric acid gaba enhancers

Pharmacokinetics

Absorption: Extent of absorption following oral administration unknown. Absorption with fat-containing foods.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Extensively metabolized in the liver via the CYP3A4 isoenzyme to inactive metabolites. 45% excreted in urine; 41% excreted in feces primarily as metabolites.

Half-Life: 19.7–24.6 hr.

Contr. Subst. Schedule

Schedule IV (C-IV)

Time/Action Profile

( in depressive symptoms)
ROUTEONSETPEAKDURATION
PO3 daysunknownat least 45 days



Patient/Family Teaching

Pronunciation

zoo-RAN-oh-lone